<DOC>
	<DOCNO>NCT01882296</DOCNO>
	<brief_summary>Primary object : Evaluate Pharmacodynamic property safety administer S-pantoprazole 10 , 20 , 40mg Pantoprazole 20 , 40mg healthy male subject Secondary object : Evaluate Dose-response S-pantoprazole pantoprazole compare dose-response</brief_summary>
	<brief_title>Investigate Pharmacodynamics Between S-pantoprazole 10 , 20 , 40mg Pantoprazole 20 , 40mg Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Adult healthy male 20 45 year screen BMI : 19kg/m2 ~ 26 kg/m2 Blood Pressure : `` 140 mmHg ≥ sit SBP ≥ 90 mmHg , 95 mmHg ≥ sit DBP ≥ 50 mmHg '' Have history significant hepatic , renal gastrointestinal , pulmonary , musculoskeletal , endocrine , neuropsychiatric , hematologic , cardiovascular disease Have gastrointestinal disease ( ex : Crohn 's disease , gastrointestinal ulcer ) surgery ( except Appendectomy , hernia repair ) affect absorption medication Have history GERD , Gastric ulcer , Duodenal ulcer H.pylori positive Hypersensitivity reaction drug clinically significant hypersensitivity reaction history benzimidazole ( ex : pantoprazole , NSAID , antibiotic ) Have history drug abuse unusual diet affect absorption , distribution , metabolism , excretion medication Subject treat investigational drug within 90 day administration investigational drug Subject take inhibitor inducer drug metabolize enzyme ( Barbiturates etc . ) within 30days Previously donate whole blood within 60 day component blood within 30 day transfusion within 30 day Subject take habitually caffeine ( caffeine &gt; 5 units/day ) Subject drunken habitually ( alcohol &gt; 21 units/week , 1 unit = pure alcohol 10ml ) unable quit drinking study smoker Subjects deem ineligible investigator base reason</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>